Please login to the form below

Deal Watch table for March 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during March 2014.

For an indepth analysis of these deals, read 'Pharma deals during March 2014'

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Vidara Therapeutics/ Horizon Pharma	Merger/ acquisition	Actimmune (interferon gamma-1b) for CGD and SMO (approved)	660
Five Prime Therapeutics/ BMS	Collaboration, licence	Drug discovery against two undisclosed targets in immune checkpoint pathways	350.5
AnaptysBio/ Tesaro	Collaboration, licence	mAbs to activate immune system response "checkpoints" - 3 targets: TIM-3, LAG-3 and PD-1 (preclinical)	341
Revive Pharmaceuticals/ Concordia Healthcare	Product acquisition	Donnatal, adjunctive therapy for IBS and acute enterocolitis (marketed)	265.3
*Takeda Pharmaceutical/ Otsuka Pharmaceutical	Co-promotion	TAK-438 (vonoprazan fumarate) for acid-related diseases (NDA filed JP)	195+
Galapagos/ Charles River	Acquisition of CRO business	Drug discovery services business	185
Activaero/ Vectura	Acquisition (cash + equity)	Portfolio of nebuliser-based respiratory products and technologies	181
Caisson Biotech/ Novo Nordisk	Licence	HEPtune drug delivery technology for half-life extension - insulin and other therapeutics (preclinical)	167
UCB/ Sanofi	Collaboration - discovery/ development	Anti-inflammatory small molecules for treatment of immune-mediated disorders (discovery)	138.5
TxCell/ Ferring	Collaboration, option, licence	Ovasave - personalised cell-based immunotherapy for IBD (inc Crohn's disease, ulcerative colitis) (p2)	105
Sumitomo Chemical/ AstraZeneca	Acquisition of remaining shares	AZ takes complete control of AstraZeneca KK	102
**Bayer/ Kythera Biopharmaceuticals	Buy back of rights ex US, Canada (Aug 2010 deal)	ATX-101 - submental contouring injectable drug (p3)	84
Sarasvati Venture Capital/ GSK	Acquisition of remaining 30% shares	GSK takes full control of its Indonesian consumer health unit	26.6
‡SK Chemicals/ Sanofi Pasteur	Collaboration	Pneumococcal conjugate vaccine (PCV)	23
Genmab/ Janssen	Milestone payment	Daratumumab, anti-CD38 mAb for multiple myeloma (p2 milestone)	22
Tracon Pharmaceuticals/ Santen Pharmaceutical Co	Licence	Tracon's anti‐endoglin antibodies, including TRC105 for wet AMD (p2)	10
‡‡BioAlliance Pharma/ Innocutis	Licence	Sitavig® (acyclovir Lauriad®) for recurrent herpes labialis (approved)	5

All deals are worldwide unless otherwise noted – see below:

*       Japan
**     Outside US, Canada
‡         Sanofi Pasteur has rights outside Korea; SK has exclusive rights for Korea
‡‡     North America

CGD = chronic granulomatous disease
SMO = severe, malignant osteopetrosis

The Deal Watch table is compiled by Medius Associates

11th April 2014